- All Drug Categories
- Home
- Anti-cancer Drugs
- Healthcare Products
- Medical Information
- Statement
Epclusa is a compound formulation composed of sofosbuvir and velpatasvir, specifically designed for the treatment of chronic hepatitis C virus ...
Dasatinib, as a tyrosine kinase inhibitor, has contraindications mainly related to specific disease states, drug interactions, and special popu...
Epclusa is a compound formulation composed of Sofosbuvir and Velpatasvir. It is the world's first oral antiviral drug for the full genotype hep...
The recommended medication time for Epclusa is fixed daily and can be taken on an empty stomach or after a meal, but attention should be paid t...
Axitinib is a tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR), mainly used for second-line treatment of advanc...
Axitinib is an oral small molecule tyrosine kinase inhibitor primarily used as second-line therapy for advanced renal cell carcinoma, blocking ...
Axitinib is a VEGFR tyrosine kinase inhibitor mainly used for second-line treatment of advanced renal cell carcinoma. Its target population nee...
Axitinib, as a targeted therapy drug, must strictly follow specific restrictions on its use, including contraindications, dosage adjustment r...
Cobimetinib, as a MEK1/2 inhibitor, has significant therapeutic effects on BRAFV600 mutation positive unresectable or metastatic melanoma. Its ...
The use of Cobimetinib should strictly follow the indications and combination therapy regimen. It is mainly suitable for BRAFV600 mutation posi...
